CRISPR/Cas9 mediated CXCL4 knockout in human iPS cells of polycythemia vera patient with JAK2 V617F mutation

Stem Cell Res. 2021 Aug;55:102490. doi: 10.1016/j.scr.2021.102490. Epub 2021 Aug 5.

Abstract

The chemokine CXCL4/platelet factor 4 (PF4) gene, a key player in myelofibrosis, was knocked out by CRISPR/Cas9 in induced pluripotent stem cells (iPS cells) of a polycythemia vera (PV) patient with JAK2 V617F mutation. Two CXCL4KO iPS cell lines with and without JAK2 V617F mutation (UKAi002-B-1 and UKAi002-A-1, respectively) were generated. CXCL4KO iPS cells showed deletion of exon 1 and complete loss of CXCL4 protein. Pluripotency of iPS cells was confirmed by expression of pluripotency markers and trilineage differentiation. CXCL4KO iPS cells are expected to provide a valuable tool for investigating the role of CXCL4 in human diseases.

Keywords: CXCL4; Hematopoiesis; Induced pluripotent stem cell; JAK2 V617F; PF4; iPS cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CRISPR-Cas Systems / genetics
  • Humans
  • Induced Pluripotent Stem Cells* / metabolism
  • Janus Kinase 2 / genetics
  • Janus Kinase 2 / metabolism
  • Mutation
  • Polycythemia Vera* / genetics

Substances

  • JAK2 protein, human
  • Janus Kinase 2